Abstract
Metazoan organisms may discriminate between self and non-self not only by the presence of foreign antigens but also by the absence of normal self markers1. Mammalian adaptive immune responses use the first strategy, with the additional requirement that foreign antigens are recognized in the context of self-major histocompatibility complex (MHC) products at the cell surface2. Aberrant cells which fail to express MHC products adequately can therefore avoid detection2–4. A more primitive but complementary defence system, eliminating such cells on the basis of absent self-markers, is suggested by a re-interpretation5,6 of phenomena associated with metastasis and natural resistance. We now show that murine lymphoma cells selected for loss of H–2 expression are less malignant after low-dose inoculation in syngeneic hosts than are wild-type cells, and that the rejection of such cells is non-adaptive. On the basis of our data, we suggest that natural killer cells are effector cells in a defence system geared to detect the deleted or reduced expression of self-MHC.
Similar content being viewed by others
Article PDF
References
Burnet, F. M. Nature 232, 230–235 (1971).
Zinkernagel, R. M. & Doherty, P. C. J. exp. Med. 141, 1427–1436 (1975).
Doherty, P. C., Knowles, B. B. & Wettstein, P. J. Adv. Cancer Res. 42, 1–66 (1984).
Sanderson, A. R. & Beverley, P. C. L. Immun. Today 4, 211–213 (1983).
Kärre, K. thesis, Karolinska Inst. (1981).
Kärre, K. in Mechanisms of Cytoxicity by Natural Killer Cells (eds Herberman, R. B. & Callewaert, D.) 81–91 (Academic, Orlando, 1985).
Kärre, K., Klein, G. O., Kiessling, R., Klein, G. & Roder, J. C. Int. J. Cancer 26, 789–797 (1980).
Klein, J. in Biology of the Mouse Histocompatibility-2 Complex, 36–37 (Springer, New York, 1975).
Boon, R., Adv. Cancer Res. 39, 121–151 (1983).
Frost, P., Kerbel, R. S., Bauer, E., Tartanella-Biondo, R. & Cefalu, W. Cancer Res. 43, 125–132 (1983).
Hui, K., Grosvels, F. & Festenstein, H. Nature 311, 750–752 (1984).
Hämmerling, G. J. et al. Nature 315, 301–306 (1985).
Bevan, M. J. J. exp. Med. 142, 1349–1364 (1975).
Cudkowicz, G. & Hochman, P. S. Immun. Rev. 44, 13–41 (1979).
Cikes, M., Friberg, S. Jr & Klein, G. J. natn. Cancer Inst. 30, 347–361 (1973).
Stern, P. et al. Nature 285, 341–342 (1982).
Hansson, M. et al. J. Immun. 123, 765–771 (1979).
Carlson, G. A., Melnychuk, D. & Meeker, M. J. Int. J. Cancer 25, 111–122 (1980).
Hansson, M., Kiessling, R., Andersson, B. & Welsh, R. M. J. Immun. 125, 2225–2231 (1980).
Becker, S., Kiessling, R., Lee, N. & Klein, G. J. natn. Cancer Inst. 61, 1493–1498 (1978).
Cudkowicz, G. & Bennet, M. J. exp. Med. 134, 1513–1528 (1971).
Klein, G. O., Klein, G., Kiessling, R. & Kärre, K. Immunogenetics 6, 561–569 (1978).
Rolstad, B. & Ford, W. L. Immun. Rev. 73, 87–114 (1983).
Möller, E. J. natn. Cancer Inst. 33, 979–987 (1964).
Haywood, G. R. & McKhann, C. J. exp. Med. 133, 1171–1187 (1971).
Katzav, S., De Baetselier, P., Tarbakovsky, B., Feldman, M. & Segal, S. J. natn. Cancer Inst. 71, 317–324 (1983).
Eisenbach, L., Segal, S. & Feldman, M. Int. J. Cancer 32, 113–120 (1983).
Gooding, L. R. J. Immun. 129, 1306–1312 (1982).
Schrier, P. I., Bernards, R., Vaessen, J., Houweling, A. & van der Eb, A. J. Nature 305, 771–775 (1983).
Gidlund, M. et al. Nature 292, 848–850 (1981).
Scofield, V. L., Schlumpberger, J. M., West, L. A. & Weissman, I. L. Nature 295, 499–502 (1982).
Hecht, T. & Summers, D. J. Virol. 10, 378–385 (1972).
Welsh, R.M., Kärre, K., Hansson, M., Kunkel, L.A. & Kiessling, R. J. Immun. 126, 219–225 (1981).
Snell, G. Transplantn Proc. 8, 147–156 (1976).
Dausset, J. Devl comp. Immun. 5, 1–4 (1981).
Brickell, P. M., Latchman, D., Murphy, D., Wilson, K. & Rigby, P. W. J. Nature 306, 756–761 (1984).
Baldacci, P., Pozo, F., Gisselbrecht, S. & Kourilsky, P. J. exp. Med. 158, 1294–1306 (1981).
Ozato, K. & Sachs, D. H. J. Immun. 126, 317–321 (1981).
Kärre, K., Seeley, J., Eriksson, E., Burton, R. & Kiessling, R. J. exp. Med. 156, 385–403 (1983).
Julius, M. H., Simpson, E. & Herzenberg, L. A. Eur. J. Immun. 3, 645–651 (1973).
Piontek, G. et al. J. Immun. 135, 4281–4288 (1985).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kärre, K., Ljunggren, H., Piontek, G. et al. Selective rejection of H–2-deficient lymphoma variants suggests alternative immune defence strategy. Nature 319, 675–678 (1986). https://doi.org/10.1038/319675a0
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/319675a0
This article is cited by
-
Chimeric antigen receptor-based natural killer cell immunotherapy in cancer: from bench to bedside
Cell Death & Disease (2024)
-
How adoptive transfer of components of the donor immune system boosts GvL and prevents GvHD in HLA-haploidentical hematopoietic transplantation for acute leukemia
Bone Marrow Transplantation (2024)
-
Survival mechanisms of circulating tumor cells and their implications for cancer treatment
Cancer and Metastasis Reviews (2024)
-
Hypoimmune induced pluripotent stem cells survive long term in fully immunocompetent, allogeneic rhesus macaques
Nature Biotechnology (2024)
-
Phase I non-randomized clinical trial of allogeneic natural killer cells infusion in acute myeloid leukemia patients
BMC Cancer (2023)
